11:54:21 EDT Fri 30 Sep 2022
Enter Symbol
or Name

Login ID:
Tilray Brands Inc
Symbol TLRY
Shares Issued 446,156,841
Close 2022-06-28 C$ 4.46
Recent Sedar Documents

Tilray Brands adds to U.K. medical pot portfolio

2022-06-29 09:37 ET - News Release

Ms. Denise Faltischek reports


Tilray Brands Inc.'s medical cannabis division, Tilray Medical, has expanded its medical cannabis offerings in the United Kingdom. Tilray Medical now offers the broadest portfolio of cannabis flower in the U.K. market today, including a differentiated range of high-THC (tetrahydrocannabinol) products, cultivated at its EU-GMP-certified (European Union good manufacturing practice) facility in Portugal.

Denise Faltischek, Tilray's chief strategy officer and head of international business, said: "The demand for medical cannabis in the U.K. is growing rapidly. We are incredibly proud to provide patients in the U.K. with high-quality, consistent medical cannabis products they can rely on and are accessible to them."

Tilray Medical now offers an extensive selection of medical cannabis products, including a market-leading portfolio of cannabis flowers with THC potencies that span from 10 per cent to 25 per cent, and offer a range of different ratios. Tilray Medical's portfolio in the U.K. is underpinned by a breadth of cultivars, each with a unique profile of cannabinoids and terpenes, that have been selected to ensure patients can receive both the highest product quality as well as consistency when it comes to supply of their medicinal cannabis products. By offering such a broad range of cannabis flower products in the U.K., Tilray Medical hopes to expand the range of treatment options available to patients and ensure prescribers and patients are provided with a safe and reliable choice as they embark on their medical cannabis journey.

In the U.K., patients may obtain prescriptions for medical cannabis through their specialist doctor. Tilray Medical supplies the U.K. and the rest of its international business with EU-GMP-certified medical cannabis from its state-of-the-art facilities in Portugal, providing patients with safe and reliable access to high-quality medical cannabis.

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast and Symbios. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first EU-GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers and governments, in 20 countries and across five continents.

About Tilray Brands Inc.

Tilray Brands is a leading global cannabis lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is changing people's lives for the better -- one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body and soul while invoking well-being. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and well-being through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray's unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.